| Literature DB >> 28579146 |
José Bourbon-Teles1, Sonya Bells1, Derek K Jones2, Elizabeth Coulthard3, Anne Rosser4, Claudia Metzler-Baddeley5.
Abstract
Huntington's disease (HD) leads to white matter (WM) degeneration that may be due to an early breakdown in axon myelination but in vivo imaging correlates of demyelination remain relatively unexplored in HD compared to other neurodegenerative diseases. This study investigated HD-related effects on a putative marker of myelin, the macromolecular proton fraction (MMPF) from quantitative magnetization transfer and on fractional anisotropy, axial and radial diffusivity from diffusion tensor MR-imaging. Microstructural differences were studied in WM pathways of the basal ganglia and motor systems known to be impaired in HD: the corpus callosum, the cortico-spinal tract, the anterior thalamic radiation, fibers between prefrontal cortex and caudate and between supplementary motor area and putamen. Principal component analysis was employed for dimensionality reduction. Patients showed reductions in a component with high loadings on MMPF in all WM pathways and a trend for increases in a component loading on axial and radial diffusivities but no differences in a component loading on fractional anisotropy. While patients' performance in executive functioning was impaired, their working memory span was preserved. Inter-individual differences in the diffusivity component correlated with patients' performance in clinical measures of the United Huntington Disease Rating Scale. In summary, HD-related reductions in MMPF suggest that myelin breakdown contributes to WM impairment in human HD and emphasize the potential of quantitative MRI metrics to inform about disease pathogenesis. Disease severity in manifest HD, however, was best captured by non-specific diffusivity metrics sensitive to multiple disease and age-related changes.Entities:
Keywords: Huntington’s disease; basal ganglia; clinical markers; cognition; myelin; white matter
Mesh:
Year: 2017 PMID: 28579146 PMCID: PMC6458992 DOI: 10.1016/j.neuroscience.2017.05.042
Source DB: PubMed Journal: Neuroscience ISSN: 0306-4522 Impact factor: 3.590
Fig. 1White matter pathway regions of interest. Sagittal and axial views of the reconstructed white matter pathways displayed on a T1-weighted image for one control participant. (A) segments I, II, and III of the corpus callosum (Hofer and Frahm, 2006), (B) anterior thalamic radiation, (C) prefrontal cortex – caudate pathway, (D) cortico-spinal tract and (E) supplementary motor area – putamen pathway. Fiber directions are color-coded with green indicating directions along the coronal, blue along the axial and red along the sagittal plane (Pajevic and Pierpaoli, 1999). (F) displays all reconstructed pathways on a sagittal view of the left hemisphere for another control participant. The corpus callosum segments are displayed in red (segment I) and orange (segments II and III), the anterior thalamic radiation in yellow, the prefrontal cortex – caudate fibers in blue, the supplementary motor area – putamen fibers in dark blue and the cortico-spinal tract in green.
Patients’ demographics and background clinical information
| Patients | Age | Sex | Length of CAG repeats | TMS | FAS | Medication |
|---|---|---|---|---|---|---|
| HD01 | 42 | F | 45 | 41 | 21 | Olanzepine 5 mg, Citalopram 20 mg, Pregabalin 50 mg, Depakote 250 mg |
| HD02 | 46 | F | 40 | 9 | 24 | Nil |
| HD03 | 24 | M | 43 | 2 | 25 | Nil |
| HD04 | 38 | F | 45 | 10 | 22 | Amitriptyline 75 mg, Omeprazole 10 mg, Prochlorperazine 10 mg, |
| HD05 | 60 | M | 43 | 48 | 17 | Olanzepine 12 mg |
| HD06 | 45 | F | 42 | 46 | 16 | Natriliz 1.5 mg, Rosuvasatin 10 mg, Atenolol 25 mg Carioplan 5 mg, Quetiapine 700 mg Metformin 500 mg, Indomethocin 25 mg, Pendopril 4 mg |
| HD07 | 55 | M | 43 | 82 | 13 | Olanzapine 20 mg, Propanolol 30 mg, Cetrizine, Fortisips, Temazepam 10 mg |
| HD08 | 49 | M | 42 | 7 | 23 | Nil |
| HD09 | 64 | M | 41 | 19 | 23 | Citalopram 40 mg |
| HD10 | 44 | F | 47 | 72 | 1 | Trazodone 300 mg, Abilify 5 mg, Temazepam 10 mg, Pregabalin 150 mg. |
| HD11 | 44 | F | 46 | 35 | 24 | Citalopram 40 mg, Zopiclone 37.5 mg, Co-codamol 2 tables |
| HD12 | 64 | M | 40 | 35 | 22 | Aspirin 75 mg, Atorvastatin 40 mg, Perindopril 4 mg, Sumatriptan 50 mg |
| HD13 | 46 | M | 45 | 35 | 13 | Gabapentin 600 mg, Citalopram 30 mg, |
| HD14 | 22 | M | 51 | 17 | 23 | Citalopram 30 mg |
| HD15 | 28 | F | 51 | 61 | 18 | Perampanel 8 mg, Lamotrigine 100 mg, Levetiracetam 1500 mg, Clobazam up to 10 mg |
| HD16 | 47 | M | 46 | 69 | 18 | Sertraline 50 mg, |
| HD17 | 62 | F | 41 | 4. | 25 | Novate ointments, Naproxen |
| HD18 | 50 | M | 40 | 0 | 25 | Nil |
| HD19 | 68 | F | 43 | 40 | 17 | Mirtazapine 30 mg |
| HD20 | 58 | M | 43 | 0 | 25 | Atorvastatin 20 mg |
| HD21 | 58 | M | 41 | 37 | 25 | Amlodipine 5 mg, Bendroflumethiazide 2.5 mg, Metformin 500 mg, Ramipril 2.5 mg, Sertraline 100 mg |
| HD22 | 30 | F | 42 | 0 | 25 | Nil |
| HD23 | 37 | F | 46 | 6 | 25 | Co-codamol 30/500, Omeprazole 10 mg, Ventolin inhaler 2 puffs, Amitriptyline 50 mg |
| HD24 | 51 | M | 43 | 20 | 23 | Co-codamol 500 mg, Brufen 400 mg |
| HD25 | 47 | F | 41 | 5 | 25 | Kliofem 2 mg, Amitriptyline 150 mg, Omeprazole 20 mg, Rizatriptan 10 mg, Loratidine 10 mg |
| Mean | 47.2 | – | 44 | 28 | 20.7 | |
| SD | 12.5 | 3.1 | 24.9 | 5.65 |
Abbreviations: CAG = cytosine-adenine-guanine, F = Female, M = Male, TMS = Total Motor Score out of 124 (the higher the scores the more impaired the performance). FAS = Functional Assessment Score out of 25 (the higher the scores the better the performance). HD = Huntington’s disease, SD = Standard Deviation.
Rotated component matrix of the principal component analysis of the cognitive data (N = 33)a
| Cognitive Scores | “Executive function” component | “Verbal Span” component |
|---|---|---|
| −0.013 | ||
| 0.077 | ||
| 0.143 | ||
| 0.193 | ||
| 0.171 | ||
| 0.218 | ||
| −0.182 | ||
| 0.021 | ||
| 0.254 | ||
| −0.285 | ||
| −0.203 | ||
| 0.163 | ||
| 0.049 | ||
| 0.225 |
Loadings >0.5 are highlighted in bold. DSST = Digit Symbol Substitution Test, RT = Reaction Time.
Rotation method: Varimax with Kaiser normalization.
Rotated component matrix of the principal component analysis of the white matter microstructural data (N = 32)a
| Tract-specific white matter microstructural metrics | “Diffusivity” component | “MMPF” component | “FA” component | |
|---|---|---|---|---|
| ATR | Left | −0.18 | −0.03 | |
| Right | −0.13 | −0.17 | ||
| CC1 | −0.18 | −0.12 | ||
| CC2 | −0.38 | −0.06 | ||
| CC3 | −0.36 | −0.01 | ||
| PFC-caudate | Left | −0.26 | 0.31 | |
| Right | −0.06 | 0.10 | ||
| SMA-putamen | Left | 0.01 | 0.15 | |
| Right | −0.01 | −0.04 | ||
| CST | Left | 0.01 | −0.07 | |
| Right | −0.13 | −0.03 | ||
| ATR | Left | −0.21 | 0.24 | |
| Right | −0.13 | 0.26 | ||
| CC1 | −0.15 | 0.37 | ||
| CC2 | 0.44 | 0.19 | −0.10 | |
| CC3 | 0.16 | 0.30 | −0.24 | |
| PFC-caudate | Left | −0.13 | 0.28 | |
| Right | −0.11 | 0.33 | ||
| SMA-putamen | Left | −0.23 | 0.17 | |
| Right | −0.21 | 0.16 | ||
| CST | Left | −0.15 | 0.03 | |
| Right | −0.42 | −0.11 | ||
| ATR | Left | −0.09 | −0.49 | |
| Right | −0.10 | −0.34 | ||
| CC1 | −0.13 | −0.17 | ||
| CC2 | −0.04 | −0.24 | ||
| CC3 | −0.02 | −0.14 | ||
| PFC-caudate | Left | −0.21 | −0.36 | |
| Right | −0.39 | −0.44 | ||
| SMA-putamen | Left | 0.01 | 0.10 | |
| Right | 0.01 | 0.03 | ||
| CST | Left | 0.06 | −0.10 | |
| Right | 0.07 | 0.16 | ||
| ATR | Left | −0.07 | −0.14 | |
| Right | −0.02 | −0.01 | ||
| CC1 | 0.07 | |||
| CC2 | 0.10 | 0.30 | ||
| CC3 | 0.14 | 0.11 | ||
| PFC-caudate | Left | −0.16 | 0.13 | |
| Right | −0.11 | 0.26 | ||
| SMA-putamen | Left | −0.16 | ||
| Right | 0.47 | −0.13 | ||
| CST | Left | 0.41 | 0.06 | 0.35 |
| Right | 0.43 | −0.42 | 0.44 | |
Loadings >0.5 are highlighted in bold. Abbreviations: ATR = Anterior Thalamic Radiation, CC = Corpus Callosum, CST = Cortico-spinal Tract, FA = Fractional Anisotropy, MMPF = Macromolecular Proton Fraction, PFC = Prefrontal Cortex, SMA = Supplementary Motor Area, RD = Radial Diffusivity.
Rotation method: Varimax with Kaiser normalization.
Component matrix of the principal component analysis of the subcortical gray matter volumetric data (N = 32)a
| “BG volume” component | ||
|---|---|---|
Loadings >0.5 are highlighted in bold.
Demographics and general cognitive profile of patients and controls
| Patients ( | Controls ( | ||
|---|---|---|---|
| 48 | 50 | – | |
| 45.6 (12.7) | 51.4 (14.4) | ||
| 13.33 (2.68) | 15.0 (4.4) | ||
| 103 (12.9) | 118.9 (7.5) | ||
| 22.7 (5.6) | 27.18 (1.7) |
Abbreviations: MoCA = Montreal Cognitive Assessment score out of 30; NART-IQ = verbal IQ estimate based on the National Adult Reading Test.
One patient could not perform the NART.
Fig. 2Group differences in white matter microstructure, basal ganglia volume and cognition. (A) Mean component scores for patients with Huntington’s disease (patterned bars) and controls (white bars) of the “diffusivity” component with positive loadings on axial and radial diffusivity, of the component with positive loadings on the macromolecular proton fraction (“MMPF component”) and the component with positive loadings on fractional anisotropy (“FA” component). Patients showed significantly reduced scores in the MMPF component, a trend for increased scores in the diffusivity component but no difference in the FA component. (B) Mean component scores of the “basal ganglia (BG) volume” component with positive loadings on volumes of the caudate, putamen, pallidum and the thalamus on both hemispheres. After the exclusion of one control participant’s outlier score HD patients showed significantly reduced BG volume relative to controls. (C) Mean component scores of the ‘executive function’ component with loadings on performance in the Stroop task, Verbal and Category Fluency, Verbal Trails, Digit Symbol Substitution task and box crossing under single and dual task conditions and the “verbal span” component with loadings on performance in digit span only. Patients showed significantly reduced executive function performance but did not differ in verbal working memory capacity from the controls. Abbreviations: HD = Huntington’s Disease, FA = Fractional Anisotropy, MMPF = Macromolecular Proton Fraction, SE = Standard error.
Fig. 3Spearman rho correlations between white matter microstructure, basal ganglia volume, cognition and clinical measures. (A) A positive correlation between patients’ inter-individual variation in the diffusivity component scores and their Total Motor Score of the United Huntington’s disease Rating Scale (UHDRS). Larger scores reflect more impaired performance or microstructure respectively. Please note that this correlation remained significant after the exclusion of one outlier that can be seen in the top right corner. (B) A negative correlation between patients’ inter-individual variation in the diffusivity component and their Functional Assessment Score (FAS) of the UHDRS. Lower FAS scores reflect more severe impairment. Please note that this correlation remained significant after the exclusion of the outlier in the left bottom corner. (C) A negative correlation between patients’ variation in the TMS and FAS which remained significant after outlier exclusion. (D) A positive correlation between patients’ FAS and their executive function component. (E) A negative correlation between patients TMS and their executive function component. (F) A negative correlations between inter-individual variation in the diffusivity and executive function component across patients (black diamond) and controls (white square). (G) A negative correlations between inter-individual variation in the diffusivity and basal ganglia volume component across patients (black diamond) and controls (white square).
Correlations between brain structural component, cognitive components and clinical markers
| 0.32 (0.15) | −0.03 (0.89) | |||
| −0.24 (0.28) | 0.10 (0.66) | |||
| 0.18 (0.35) | −0.34 (0.06) | |||
| −0.07 (0.71) | −0.09 (0.64) | 0.12 (0.54) | −0.04 (0.84) |
Correlations coefficients that were significant after Bonferroni correction are highlighted in bold. Trends defined as correlations significant at the uncorrected level are highlighted in italics.